Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396184 | 0.92 | HTT (0.51) | HTTMAOBGAAMAOAALDH1A1 | |
| SCHEMBL16396254 | 0.88 | RAB9A (0.60) | MAOBGAAMAOAALDH1A1RAB9A | |
| SCHEMBL16396350 | 0.87 | MAOB (0.53) | MAOBGAAMAOAALDH1A1RAB9A | |
| SCHEMBL417705 | 0.86 | MAPT (0.60) | HTTMAOBMAOAALDH1A1RAB9A | |
| SCHEMBL8403461 | 0.83 | ALDH1A1 (0.65) | HTTMAOBGAAMAOAALDH1A1 | |
| SCHEMBL16396263 | 0.78 | VNN1 (0.56) | MAOBMAOAALDH1A1RAB9AMAPT | |
| SCHEMBL6841271 | 0.77 | MAPT (0.53) | MAOBMAOAALDH1A1MAPTALOX5 | |
| SCHEMBL2367158 | 0.77 | NPC1 (0.68) | HTTMAPTMAPK1ALOX5SMN1; SMN2 | |
| SCHEMBL10651178 | 0.76 | MAOB (0.68) | MAOBALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL5708159 | 0.76 | HTT (0.57) | HTTGAAALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | HTT 1660/4885MAOB 4473/4885GAA 3188/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | HTT 1660/4885MAOB 4473/4885GAA 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.